298 related articles for article (PubMed ID: 19567878)
1. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Jabbour E; Jones D; Kantarjian HM; O'Brien S; Tam C; Koller C; Burger JA; Borthakur G; Wierda WG; Cortes J
Blood; 2009 Sep; 114(10):2037-43. PubMed ID: 19567878
[TBL] [Abstract][Full Text] [Related]
2. ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Wang Z; Liu Z; Wu X; Chu S; Wang J; Yuan H; Roth M; Yuan YC; Bhatia R; Chen W
PLoS Genet; 2014 Jun; 10(6):e1004414. PubMed ID: 24967705
[TBL] [Abstract][Full Text] [Related]
3. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Jabbour E; Branford S; Saglio G; Jones D; Cortes JE; Kantarjian HM
Cancer; 2011 May; 117(9):1800-11. PubMed ID: 21509757
[TBL] [Abstract][Full Text] [Related]
4. Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.
Santos FP; Ravandi F
Leuk Lymphoma; 2009 Dec; 50 Suppl 2(0 2):16-26. PubMed ID: 20017607
[TBL] [Abstract][Full Text] [Related]
5. Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
Iqbal Z; Aleem A; Iqbal M; Naqvi MI; Gill A; Taj AS; Qayyum A; ur-Rehman N; Khalid AM; Shah IH; Khalid M; Haq R; Khan M; Baig SM; Jamil A; Abbas MN; Absar M; Mahmood A; Rasool M; Akhtar T
PLoS One; 2013; 8(2):e55717. PubMed ID: 23409026
[TBL] [Abstract][Full Text] [Related]
6. [Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia].
Shi DY; Qin YZ; Lai YY; Shi HX; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):469-476. PubMed ID: 32654459
[No Abstract] [Full Text] [Related]
7. [Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].
Jiang Q; Qin Y; Lai Y; Jiang H; Shi H
Zhonghua Xue Ye Xue Za Zhi; 2016 Jan; 37(1):7-13. PubMed ID: 26876246
[TBL] [Abstract][Full Text] [Related]
8. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
[TBL] [Abstract][Full Text] [Related]
9. Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors.
Ursan ID; Jiang R; Pickard EM; Lee TA; Ng D; Pickard AS
J Manag Care Spec Pharm; 2015 Feb; 21(2):114-22. PubMed ID: 25615000
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia therapy in the era of tyrosine kinase inhibitors--the first molecular targeted treatment.
Bumbea H; Vladareanu AM; Voican I; Cisleanu D; Barsan L; Onisai M
J Med Life; 2010; 3(2):162-6. PubMed ID: 20968202
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Stein B; Smith BD
Clin Ther; 2010 May; 32(5):804-20. PubMed ID: 20685492
[TBL] [Abstract][Full Text] [Related]
12. Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Levinson NM; Boxer SG
PLoS One; 2012; 7(4):e29828. PubMed ID: 22493660
[TBL] [Abstract][Full Text] [Related]
13. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
Cornelison AM; Kantarjian H; Cortes J; Jabbour E
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S101-10. PubMed ID: 22035738
[TBL] [Abstract][Full Text] [Related]
14. Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
Ferrari-Amorotti G; Keeshan K; Zattoni M; Guerzoni C; Iotti G; Cattelani S; Donato NJ; Calabretta B
Blood; 2006 Aug; 108(4):1353-62. PubMed ID: 16670262
[TBL] [Abstract][Full Text] [Related]
15. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Jabbour E; Cortes JE; Kantarjian HM
Mayo Clin Proc; 2009 Feb; 84(2):161-9. PubMed ID: 19181650
[TBL] [Abstract][Full Text] [Related]
16. Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.
Leder K; Foo J; Skaggs B; Gorre M; Sawyers CL; Michor F
PLoS One; 2011; 6(11):e27682. PubMed ID: 22140458
[TBL] [Abstract][Full Text] [Related]
17. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Kantarjian H; Cortes J; Kim DW; Dorlhiac-Llacer P; Pasquini R; DiPersio J; Müller MC; Radich JP; Khoury HJ; Khoroshko N; Bradley-Garelik MB; Zhu C; Tallman MS
Blood; 2009 Jun; 113(25):6322-9. PubMed ID: 19369231
[TBL] [Abstract][Full Text] [Related]
18. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
Press RD; Willis SG; Laudadio J; Mauro MJ; Deininger MW
Blood; 2009 Sep; 114(13):2598-605. PubMed ID: 19625707
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Okabe S; Tauchi T; Tanaka Y; Sakuta J; Ohyashiki K
Oncotarget; 2016 Aug; 7(33):53116-53126. PubMed ID: 27437766
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Bose P; Perkins EB; Honeycut C; Wellons MD; Stefan T; Jacobberger JW; Kontopodis E; Beumer JH; Egorin MJ; Imamura CK; Douglas Figg W; Karp JE; Koc ON; Cooper BW; Luger SM; Colevas AD; Roberts JD; Grant S
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1657-67. PubMed ID: 22349810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
